2021
Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC).
Psyrri A, Moutafi M, Koliou G, Papaxoinis G, Gavrielatou N, Economopoulou P, Kotsantis I, Gkotzamanidou M, Anastasiou M, Pectasides D, Fernandez A, Yaghoobi V, Shafi S, Vathiotis I, Aung T, Gkolfinopoulos S, Foukas P, Fountzilas G, Rimm D. Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2021, 39: 6064-6064. DOI: 10.1200/jco.2021.39.15_suppl.6064.Peer-Reviewed Original ResearchCombined positive scorePD-L1 expressionQuantitative immunofluorescencePD-L1Preclinical modelsCD8 T cell infiltrationNeck squamous cell carcinomaPhase II trialReal-time quantitative reverse transcription polymerase chain reactionT cell infiltrationPD-L1 upregulationSquamous cell carcinomaPD-L1 mRNAQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionBiomarker groupsWindow studyTranscription-polymerase chain reactionSTING protein levelsPost-treatment samplesII trialAntitumor immunityImmune infiltratesPD-1Dual blockade
2018
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB, Xu Y, Sosman JA, Davis RS, Balko JM. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight 2018, 3: e120360. PMID: 30568030, PMCID: PMC6338319, DOI: 10.1172/jci.insight.120360.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityAnimalsAntibodies, NeutralizingAntigens, CDBreast NeoplasmsCD4-Positive T-LymphocytesCell Line, TumorHistocompatibility Antigens Class IIHLA-DR AntigensHumansImmunotherapyKiller Cells, NaturalLigandsLymphocyte Activation Gene 3 ProteinMiceProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellReceptors, Cell SurfaceT-LymphocytesTumor MicroenvironmentConceptsMHC-II expressionT cellsAnti-PD-1 therapyTumor cellsPD-1 pathwayTumor-intrinsic factorsPD-1-targeted immunotherapiesMHC-II receptorsDurable responsesPD-1Immune activationImmunotherapy targetPreclinical modelsLAG-3TumorsUnique patternMHCEnhanced expressionInhibitory functionAdaptive resistanceNovel inhibitory functionImmunotherapyPatientsContext-dependent mechanismsCells
2012
Cytoplasmic Estrogen Receptor in Breast Cancer
Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL. Cytoplasmic Estrogen Receptor in Breast Cancer. Clinical Cancer Research 2012, 18: 118-126. PMID: 21980134, PMCID: PMC3263348, DOI: 10.1158/1078-0432.ccr-11-1236.Peer-Reviewed Original ResearchConceptsEstrogen receptorCytoplasmic stainingCytoplasmic ERCytoplasmic estrogen receptorSpecific cytoplasmic stainingCell line seriesHuman breast tumorsQuantitative immunofluorescent analysisRoutine clinical valueRetrospective cohortTamoxifen resistanceBreast cancerLower incidencePreclinical modelsClinical valueTissue microarrayPatient controlsBreast tumorsNumber of casesClinical specimensMultiple antibodiesWestern blotAverage incidenceAntibodiesCohort
2003
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.
Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research 2003, 63: 8103-7. PMID: 14678960.Peer-Reviewed Original ResearchConceptsATF2 expressionTranscription factor 2Melanoma specimensUseful prognostic markerEarly-stage melanomaWeak cytoplasmic stainingStrong nuclear stainingFactor 2Mean followCutaneous specimensLocalized diseaseOverall survivalIndependent predictorsPreclinical findingsClark levelClinicopathological dataPatient survivalPoor outcomePrognostic valueWorse outcomesPrognostic markerPoor survivalPreclinical modelsClinical significanceImmunohistochemical staining